RonaldJBuckanovichMD

Oncology • Pittsburgh, PA

Physician

Join to view full profile

Dr. Buckanovich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Buckanovich's full profile

Already have an account?

Office
5115 Centre Avenue
B1 Floor Cancer Recp C
Pittsburgh, PA 15232
Phone+1 734-647-8906

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Pennsylvania Health SystemResidency, Internal Medicine, 1998 - 2001
Weill Cornell MedicineClass of 1998

Certifications & Licensure

PA State Medical License 1999 - 2024
MI State Medical License 2006 - 2019
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Elected Member The American Society for Clinical Investigation, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
Active, not recruiting
Phase 1, Phase 2
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients Start of enrollment: 2011 Oct 01
Completed
Phase 2
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Start of enrollment: 2013 Apr 29
Active, not recruiting
Phase 2
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Start of enrollment: 2017 Jun 10
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Identification of the MRTFA/SRF pathway as a critical regulator of quiescence in cancer.
Santiago Panesso-Gómez, Alexander J Cole, Alyssa Wield, Vivian I Anyaeche, Jaynish Shah
Biorxiv. 2024-11-17
Lymph node dissection after neoadjuvant chemotherapy improves overall survival in clinical stage III endometrial cancer.
Megan E Lander, John A Vargo, Ronald Buckanovich, Alison Garrett, Parul Barry
International Journal of Gynecological Cancer. 2024-11-04
Acetate drives ovarian cancer quiescence via ACSS2-mediated acetyl-CoA production.
Allison C Sharrow, Emily Megill, Amanda J Chen, Afifa Farooqi, Naveen Kumar Tangudu
Molecular Metabolism. 2024-11-01

Journal Articles

Leukemia Inhibitory Factor Functions in Parallel with Interleukin-6 to Promote Ovarian Cancer Growth
Karen McLean, Ronald J Buckanovich, Moshe Talpaz, Nature

Lectures

Changing the Perspective for ""Successful"" Maintenance Therapy
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian CancerOctober 28th, 2019
Targeting Stem-like Cells Could Prevent Ovarian Cancer RecurrenceMarch 12th, 2019
Findings Support Cancer Stem Cell Model, with ExceptionsNovember 30th, 2015
Join now to see all

Grant Support

Targeting Ovarian Tumor Associated Myeloid Cells With Nanoparticles TherapeuticsNational Cancer Institute2012
Using Embryonic Stem Cells To Re-Create A Human Tumor Microenvironment To DevelopOffice Of The Director, National Institutes Of Health2008